Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorSun Yat-sen University
About this trial
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)
Eligibility criteria
Qualifiers
Voluntarily sign a written informed consent form (ICF).
Age at the time of enrollment is between 18 years old and 85 years old, regardless of gender.
The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1.
Expected survival period ≥ 3 months.
Disqualifiers
Pregnant or lactating women.
Any past or current illness, treatment, or laboratory test abnormalities may confuse the research results, affect the full participation of the subjects in the study, or participation in the study may not be in the best interests of the subjects.
Trial design
Treatments tested in this trial
- Pucotenlimab combination with Vorolanib
Treatment groups
21 Participants
are divided into 1 treatment groupLocations
1Sun Yat-sen University Cancer Center0755, GuangzhouOther (Non U.s.), China
Sponsors and collaborators
Sun Yat-sen University
Lead sponsor
Source ClinicalTrials.gov